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Purpose: To evaluate the effect of intravitreal injection of Avastin, bevacizumab (IVA) on 
diabetic vitrectomy and on the postoperative course.
Methods: Thirty patients undergoing diabetic vitrectomy were distributed to standard vitrec-
tomy (group 1) or vitrectomy with preoperative IVA (group 2). Bevacizumab was injected 5 to 
7 days before surgery. Patients of both groups were matched as much as possible according to 
surgical indication and preoperative visual acuity. Main outcome measures were the feasibility 
of surgery and the postoperative complications. Feasibility of surgery was evaluated through 
recording surgical time, intraoperative bleeding, use of endodiathermy, relaxing retinotomies, 
use of perﬂ  uorocarbon liquid (PFCL) and silicone oil tamponade.
Results: Follow up ranged between 7 and 18 months. There was signiﬁ  cant reduction of mean 
surgical time, bleeding frequency, and diathermy use in group 2 compared to group 1. The rate 
of PFCL use and relaxing retinotomies were less in group 2 in comparison to group 1. Gas 
or air was used in 80% of patients in group 2 while silicone oil represented 60% of group 1. 
Postoperative visual acuity improvement was highly signiﬁ  cant in both groups but the differ-
ence in both groups was not statistically signiﬁ  cant. Vision improved in 87% in group 2 and 
80% in group 1. Primary anatomical attachment was achieved in 90.3% in group 2 and 86.6% 
in group 1. Rate of subsequent surgeries and persistent cataract were higher in group 1. Post-
operative bleeding was reported in 26.6% of cases in group 1 and none in group 2. In group 2, 
no complications related to avastin injection or progression of traction were reported during 
the preoperative period.
Conclusion: Preoperative IVA was helpful in achieving the surgical and anatomical goals 
by reducing the time of surgery, the intraoperative and postoperative bleeding, and the use of 
silicone oil with subsequent reduction of second surgery.
Keywords: intravitreal bevacizumab, proliferative diabetic retinopathy, diabetic vitrectomy, 
vascular endothelial growth factor, diabetic vitreous hemorrhage
Introduction
The ﬁ  rst goal of diabetic vitrectomy is to restore vision. Surgical objectives to achieve 
this goal are thorough removal of vitreous blood, reattachment of the macula, and 
removal of cataract. The second and equally important goal of surgery is to stabilize 
the diabetic neovascular process thereby producing long-term anatomic and visual 
success. The surgical objectives to accomplish this goal are removal of the vitreous 
scaffold, removal of the surface ﬁ  brovascular proliferation, and endophotocoagulation 
of the ischemic retina. Eyes in which these surgical objectives are achieved and which 
have a good 6-month outcome tend to remain stable for many years (Blankenship 1981; 
Blankenship and Machemer 1985; Meredith 1994). Tractional retinal detachment 
(TRD) and nonresolving vitreous hemorrhage are common indications for diabetic 
vitrectomy (Meredith 1994). Intraocular hemorrhage represents a serious event during 
diabetic vitrectomy. Extensive hemorrhage may prevent the successful conclusion 
of surgery. The removal of clotted blood may not only extend a preexisting retinal Clinical Ophthalmology 2008:2(4) 710
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break but also may create new retinal breaks (Lee and 
Abrams 2001).
The most common indication for reoperation after 
diabetic surgery is recurrent vitreous hemorrhage. Approxi-
mately 60% of eyes develop recurrent vitreous hemorrhage 
sometime in the postoperative period (Liggett et al 1987; 
Packer et al 1989; Meredith 1994). Hemorrhage occurs 
within the ﬁ  rst few days after surgery but may occur months 
or years later. Two thirds of all hemorrhages occur during the 
ﬁ  rst 6 months (Tolentino et al 1989). Various medications 
and surgical techniques have been utilized to prevent vitreous 
hemorrhage. Several interventions has been reported to be 
successful in preventing hemorrhage in the ﬁ  rst few days 
after surgery, but the percentage of cases with signiﬁ  cant 
hemorrhage 2–4 weeks after surgery has not been changed by 
any of these approaches. Such interventions included intrave-
nous aminocaproic acid (de Bustros et al 1985a), layering of 
sodium hyaluronate on areas of severed ﬁ  brovascular prolif-
eration (Packer et al 1989), intraocular injection of thrombin 
(de Bustros et al 1985b), and endolaser photocoagulation 
(Liggett et al 1987). Air-ﬂ  uid exchange has not been shown 
to have long term beneﬁ  cial effect (Liggett et al 1987). 
Bevacizumab (Avastin, Genentech Inc., San Francisco, CA), 
a full length humanized monoclonal antibody to vascular 
endothelial growth factor (VEGF) was approved by the US 
Food and Drug Administration (FDA) for the treatment 
for metastatic colorectal cancer (Manzano et al 2006). 
Recent reports on the intravitreal injection of Avastin (IVA) 
showed promise for targeting VEGF-implicated intraocular 
neovascularization seen in age-related macular degeneration 
(Avery et al 2006) and proliferative diabetic retinopathy 
(PDR) (Spaide and Fisher 2006). It has been recently shown 
to enhance the clearance of vitreous hemorrhage and induce 
involution of retinal neovascularization, (Avery 2006; Spaide 
and Fisher 2006; Chen and Park 2006) and anterior segment 
neovascularization (Avery 2006; Davidorf et al 2006; 
Oshima et al 2006; Grisanti et al 2006) with no reported 
complications.
This prospective comparative randomized study was 
constructed to study the effect of preoperative intravitreal 
injection of bevacizumab on the procedure of diabetic vit-
rectomy and on its postoperative course.
Methods
Thirty patients with PDR undergoing pars plana vitrectomy 
(PPV) were randomized by diagnosis into 2 groups; group 
1 undergoing PPV (15 patients) and group 2 undergoing 
PPV with preoperative IVA (15 patients) (Table 1). Cases 
of both groups were matched as possible according to sur-
gical indication and preoperative visual acuity. In group 2, 
bevacizumab was injected 5 to 7 days prior to surgery. The 
admission criteria were TRD involving or threatening the 
macula, TRD plus vitreous hemorrhage, nonclearing vitreous 
hemorrhage of at least one month and massive pre-retinal 
subhyaloid bleeding covering the posterior pole. Full preop-
erative and postoperative evaluation included best-corrected 
visual acuity (VA), fundus biomicroscopy, gonioscopy, and 
ultrasonography if the fundus could not be seen. All the 
patients were examined postoperatively at 1, 7 days, 2 weeks, 
1 month, and thereafter monthly up to the end of follow-up. 
The main outcome measures were feasibility of surgery 
and postoperative complications. Feasibility of surgery was 
evaluated through recording the time of surgery, frequency of 
intraoperative bleeding, frequency of use of endodiathermy, 
relaxing retinotomies, use of perﬂ  uorocarbon liquid (PFCL), 
and use of silicone oil tamponade. The time of surgery was 
calculated as the time from the entry of the probes in the 
vitreous cavity till the closure of the vitrectomy ports. This 
time was calculated by revision of the video recordings of 
surgeries. Additional procedures as elective phaco-surgery 
Table 1 Age, follow-up, and distribution of cases according to surgical diagnosis
  Group 1  Group 2  P value  P value
 PPV  Avastin  + PPV  (w)  (chi)
Age, y, mean (SD)/(range)  46 (12)/(24–65)  44 (11)/(23–57)  0.7265 
Indication of surgery, n (%)      
 TRD  4  (26.7)  4  (26.7)    1
 TRD  + vitreous Hge.  6 (40)  8 (53.3)    0.7152
  Preretinal Hge.  2 (13.3)  1 (6.7)    1
  Dense vitreous Hge.  3 (20)  2 (13.3)    1
Follow-up, mo., mean (SD)/(range)  11.7 (3.0)/(7–17)  12.9 (3.2)/(7–18)  0.2869 
Abbreviations: SD, standard deviation; TRD, tractional retinal detachment; Hge, hemorrhage; Y, years; mo, months; PPV, pars plana vitrectomy; w, Wilcoxon two-sample test; 
chi, chi square test.Clinical Ophthalmology 2008:2(4) 711
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as well as periods of time wasted outside the globe such as 
during exchange of the infusion bottle or getting a new light 
probe were excluded from the time of surgery and the actual 
surgical time was calculated by adding the time periods 
during which the instruments were inside the globe through 
strict revision of the video tapes. The decision to use gas-
air mixture or air or silicone oil was taken intraoperatively. 
The rationale for using silicone oil were; multiple breaks, 
relaxing retinotomies, and highly active retinal neovascu-
larization with signiﬁ  cant intraoperative bleeding predictive 
of postoperative hemorrhage and in cases requiring re-PPV. 
Postoperative complications including corneal erosions, 
recurrent vitreous hemorrhage, reproliferation, cataract, 
rubeosis, neovascular glaucoma, retinal detachment, were 
recorded. Complications related to IVA including increase 
of traction and any systemic side effects were recorded. All 
cases completed a minimum follow up of 6 months.
Bevacizumab injection
1.25 mg in 0.05 mL bevacizumab (Avastin, Genentech) was 
injected intravitreally under complete sterile preparation in 
the operating theater in the usual sterile fashion (Aiello et al 
2004) using topical anesthesia. Prophylactic topical antibiotic 
(moxiﬂ  oxacine) was given for 3 days postinjection.
PPV
Standard 3-port PPV utilizing Alcon Accurus surgical 
system. All surgeries were performed by the same surgeon. 
Preretinal ﬁ  brovascular membranes were removed using dif-
ferent techniques including membrane peeling, segmentation, 
delamination and en bloc dissection. High speed 23 gauge 
cutters up to 2500 cuts/minute were used to cut membranes 
very close to the retina. Bimanual technique was used when-
ever needed to safely remove membranes using the 27-gauge 
Eckardt twin light chandelier (D.O.R.C). PFCL was used to 
stabilize the retina during membrane dissection whenever 
required. Complete panretinal photocoagulation (PRP) was 
done at the end of surgery. Single raw of cryotherapy is 
applied to the anterior retinal and around the sclerotomy sites 
in an attempt to quell ﬁ  brovascular ingrowth and subsequent 
hemorrhage. No internal limiting membrane peeling was 
done in any of the surgeries. The internal tamponade used 
was decided intraoperatively, either air, Sf6/air mixture 20%, 
or silicone oil.
Statistical analysis
Visual acuity was measured using Snellen’s chart and was 
converted to Log MAR for calculation of the means. Values 
were expressed as mean ± standard deviation. Lines of vision 
lost or gained were calculated as Snellen’s lines of vision 
(via Log MAR). The Wilcoxon test was used for continuous 
variables as age and a chi square test for categorical variables. 
P  0.05 was considered statistically signiﬁ  cant. Software 
used was Stata version 6.0 (StataCorp, College Station, TX) 
(Winner 1971).
Results
Group 1 – PPV
Preoperative data
The age of the patients ranged between 24 and 65 years with a 
mean of 46 ± 12 years. Six cases had diabetes mellitus (DM) 
type Ι and 9 had type 2. All cases except 1 had previous PRP 
treatment. The distribution of cases according to indication 
for surgery was shown in Table 1. Mean preoperative visual 
acuity was 0.016 ± 6.2 lines (mean Log mar 1.81± 0.62) (range 
between HM and 0.1). Six cases (40%) had visual acuity of 
0.05 or better. Cataract phaco-surgery was done in 2 cases.
Intraoperative data
Mean surgical time was 93.3 ± 11.6 minutes (range 70 to 110 
minutes). Mean bleeding frequency was 6.8 ± 1.5 times/case 
(range between 4 and 9 bleeding attacks/case). Intraoperative 
bleeding was encountered in all cases. Diathermy was used in 
all cases with frequency of 4.6 ± 1.2 times/case (range 2 to 6 
times). Dissection under PFCL was used in 8 cases (53.3%). 
Iatrogenic breaks were reported in 6 cases (40%) and relaxing 
retinotomies in 4 cases (26.6%). Regarding intraoperative 
tamponade, gas was used in 6 cases (40%) and silicone oil 
in 9 cases (60%). The use of silicone was related to relax-
ing retinotomies and multiple breaks in 4 cases and active 
bleeding neovascularization in 5 cases (33.3%).
Postoperative data
Mean follow up period was 11.7 ± 3.04 months (range 7–17 
months). Anatomical attachment was achieved in 13 out of 15 
cases (86.6%), 2 cases (13.3%) detached due to reproliferation. 
Final visual acuity showed improvement in 12 cases (80%), 
stabilized in 2 cases (13.3%) and deteriorated in 1 eye (6.7%). 
The mean ﬁ  nal visual acuity reached 0.12 ± 6.7 lines (mean 
Log mar 0.91 ± 0.67) (range HM −0.5). This improvement of 
mean visual acuity was statistically signiﬁ  cant (p1 = 0.003). 
Four cases (26.6%) reached 20/50 or better.
Postoperative complications
Persistent cataract was reported in 7 cases (46.7 %) (all 
were silicone oil cases). Two cases (13.3%) developed gas Clinical Ophthalmology 2008:2(4) 712
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induced cataract which cleared during the ﬁ  rst week. Corneal 
erosions were observed in 5 cases (33.3%) in the early post-
operative period. Postoperative bleeding was reported in 4 
eyes (26.6%); 3 cases of which were gas treated (50% of gas 
treated cases), all of them during the ﬁ  rst 3 postoperative 
weeks and in the fourth case bleeding occurred after silicone 
removal. All cases cleared spontaneously within 3–6 weeks 
without treatment. Rubeosis was reported in 1 case (6.7%) 
under silicone oil which was associated with peripheral 
detachment in lower retina.
Subsequent surgeries: Seven cases (46.7%) treated with 
silicone oil had oil removal and cataract surgery between 
4–6 months. Two cases with redetachment underwent re-PPV 
with silicone oil.
Group 2 – PPV + bevacizumab
Preoperative data
The age of the patients ranged between 23 and 57 years with 
a mean of 44 ± 11. Seven cases had DM type Ι and 8 had 
type 2. All cases except 2 had some degree of laser treatment 
during the course of the disease. The distribution of cases 
according to indication for surgery was shown in Table 1. 
Mean preoperative visual acuity was 0.01 ± 7.3 lines (mean 
log mar 1.99 ± 0.73), (range between HM and 0.1). Five cases 
(30%) had visual acuity of 0.05 or better. Cataract surgery 
was done in 3 cases; 2 phaco and 1 ECCE.
There was evident regression of retinal neovasculariza-
tion (Figure 1) with no signiﬁ  cant deterioration of traction 
between bevacizumab injection and PPV in cases in which 
the retina could be clinically visualized.
Intraoperative data
Mean surgical time was 61.6 ± 14.5 minutes (range 
40–90 minutes). Mean bleeding frequency was 1.9 ± 1.1 
times/case (range between 0 and 4 bleeding attacks/case). 
In 2 operations, there was no bleeding at all. Diathermy 
was used only in 4 cases with mean frequency of 0.3 ± 0.46 
times/case (range 0 to1 times/case). Dissection under PFCL 
was used in 3 cases (20%). Iatrogenic breaks were reported in 
3 cases (20%) and relaxing retinotomies in 2 cases (13.3%). 
Regarding endotamponade, gas was used in 9 cases (60%), 
air was in 3 cases (20%) and silicone oil was used in 3 cases 
(20%). The use of silicone was related to multiple breaks in 
1 case, relaxing retinotomies in 1 case and relaxing retinoto-
mies with multiple breaks in 1 case.
Postoperative data
Mean follow up period was 12.9 ± 3.2 months (range 7–18 
months). Anatomical attachment was achieved in 14 out of 
15 cases (93.3%), 1 case detached due to reproliferation. 
Final visual acuity showed improvement in 13 cases (86.6%), 
no change in 2 cases (13.3%). The mean ﬁ  nal visual acuity 
reached 0.18 ± 6.8 lines (mean log mar 0.75 ± 0.68) (range 
between HM and 0.6). This improvement of mean visual 
acuity was highly signiﬁ  cant (p  0.001). Four cases (26.6%) 
reached 20/50 or better. The difference in the mean visual 
acuity between the 2 groups was not statistically signiﬁ  cant. 
(p = 0.52)
Postoperative complications were persistent cataract 
reported in 4 cases (26.6%) (3 in silicone oil cases), and three 
cases (20%) developed gas-induced cataract which cleared 
during the ﬁ  rst week. Corneal erosions were observed in 2 
cases (13.3%) in the early postoperative period. None of 
the cases reported postoperative bleeding or rubeosis. Optic 
nerve pallor was reported in 1 case.
In subsequent surgeries, 3 cases (20%) treated with 
silicone oil had oil removal and cataract surgery at some-
time during the postoperative course. One case (6.7%) with 
redetachment underwent re-PPV with cataract surgery and 
silicone oil.
Figure 1 Fundus photographs of a case in group 2.   A before injection of bevacizumab showing vitreous and subhyaloid hemorrhage and tractional retinal detachment. 
B 1 week after injection of bevacizumab showing evident regression of retinal neovascularization and C 12 months after vitrectomy with retina attached with near conﬂ  uent 
laser marks.Clinical Ophthalmology 2008:2(4) 713
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The comparative intraoperative and postoperative ﬁ  nd-
ings of both groups are summarized in Table 2.
Discussion
Pharmacological blockage of VEGF, postulated to be the 
factor which is primarily responsible for retinal angionesis 
and vascular permeability, has been investigated exten-
sively (Adamis and Shima 2005). VEGF has been shown to 
contribute signiﬁ  cantly to proliferative diabetic retinopathy. 
Retinal ischemia leads to an increased production of intra-
vitreal VEGF by pigment epithelial cells, pericytes and 
endothelial cells, while inhibition of VEGF activity via suc-
cessful panretinal photocoagulation decreases VEGF levels 
and inhibits retinal neovascularization (Aiello et al 1994).
In this study, intravitreal bevacizumab was injected in 
an effort to quiet down the ﬁ  brovascular proliferation before 
Table 2 Intraoperative and postoperative data
Group 1
PPV
Group 2
Avastin + PPV
P value
(w)
P value
(chi)
Bleeding frequency (times/surgery)
  mean (SD)/(range) 6.8 (1.5)/(4–9) 1.9 (1.1)/(0–4) 0.0001
Diathermy frequency (times/surgery)
  mean (SD)/(range) 4.6 (1.2)/(2–6) 0.27 (0.46)/(0–1) 0.0001
Surgical time (min.)
  mean (SD)/(range) 93.3 (11.6)/(70–110) 61.6 (14.5)/(40–90) 0.0001
PFCL use, n (%) 8 (53.3) 3 (20)
Relaxing retinotomy, n (%) 4 (26.6) 2 (13.3)
Endotamponade, n (%)
  20% SF6 6 (40) 9 (60)
 Air 0 3  (20)
  Silicone oil 9 (60 ) 3 (20)
VA pre surgery
 mean  (± lines)/(range) 0.016 (6.2)/(HM −0.1) 0.01(7.3)/(HM −0.1) P2  0.001
VA post surgery (ﬁ  nal) P = 0.52
 mean  (± lines)/(range) 0.12 (6.7)/(HM −0.5) 0.18 (6.8)/(HM −0.6) P1 = 0.003
VA change, n (%)
  Better 12 (80) 13 (86.6)
  Same 2 (13.3) 2 (13.3)
 Worse 1  (6.7) 0
Primary attachment, n (%) 13 (86.6) 14 (90.3) 1
Subsequent surgeries, n (%)
 Cataract  + oil removal 7 (46.7) 3 (20)
  Re-PPV 2 (13.3) 1 (6.7)
Postoperative complications
  Cataract, progressive 7 (46.7) 4 (26.6)
  Cataract, gas-induced 2 (13.3) 3 (20)
  Postoperative bleeding 4 (26.6) 0
 Rubeosis 1  (6.7) 0
  Optic pallor 0 1 (6.7)
  Corneal erosions 5 (33.3) 2 (13.3)
Abbreviations: PPV, pars plana vitrectomy; VA, best corrected visual acuity; ww, Wilcoxon two-sample test; chi, chi square test; P1, preoperative versus ﬁ  nal VA in group1; P2, 
preoperative versus ﬁ  nal VA in group 2; P, p value, visual change between the two groups; SD, standard deviation; min, minutes; PFCL, perﬂ  uorocarbon liquid.Clinical Ophthalmology 2008:2(4) 714
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vitrectomy making surgery easier. In the current study, there 
was marked reduction of intraoperative bleeding in group 
2 which was reﬂ  ected in minimal need to use the endodia-
thermy. The nearly absence of intraoperative bleeding in 
Avastin-treated cases can explain the easier dissection of 
membranes in that group. It is sometimes very difﬁ  cult to 
peel clotted blood tightly adherent to the retinal surface which 
had led to the higher incidence of retinal iatrogenic breaks in 
group 1. Lee and Abrams (2001) reported that the removal of 
hemorrhage not only may extend a preexisting retinal break, 
but also may create new retinal breaks; therefore hemorrhage 
should be avoided whenever possible. The absence of intra-
operative bleeding with evident involution of neovascular 
complex explains the higher incidence of using gas and 
air in group 2 in contrast to higher incidence of silicone oil 
in group 1. Approximately 60% of eyes develop recurrent 
vitreous hemorrhage some time in the postoperative period. 
Hemorrhage is usually within the ﬁ  rst few days after surgery 
(Liggett et al 1987; Tolentino et al 1989). Two thirds of all 
hemorrhages occur within the ﬁ  rst 6 months (Tolentino et al 
1989; Lee and Abrams 2001). Novak and colleagues (1984) 
reported that vitreous hemorrhage was present on the ﬁ  rst 
postoperative day in (63%) of eyes. This early hemorrhage 
cleared in an average of 9.1 weeks in phakic eyes and 3.4 
weeks in aphakic eyes.
In the early postoperative period, the sources of hemor-
rhage are often difﬁ  cult to determine. However, most of the 
surgeons believe that severed ﬁ  brovascular membranes are 
the usual source of bleeding which usually occurs within 1 
week of surgery (Meredith 1995; Lee and Abrams 2001). 
In the Avastin-treated cases, no postoperative bleeding was 
reported in all cases. A single dose of bevacizumab was found 
to provide complete VEGF blockade for a minimum of 4 
weeks (Beer et al 2006), thus providing a haemostatic effect 
extending beyond the absorption of the gas. This might have 
prevented recurrence of bleeding in the early postoperative 
period in group 2 giving a chance for full PRP and cryo-
therapy to induce persistent neovascular regression. In group 
1, on the other side, 3 cases out of 6 cases treated with gas 
tamponade, (50%), developed early postoperative bleeding 
while in the remaining 9 cases, the long-term silicone tam-
ponade was the main factor in preventing bleeding in the early 
postoperative period. The time of surgery was signiﬁ  cantly 
reduced in the avastin group compared to group 1. In a study 
done by Rizzo and colleagues (2007), the mean surgical time 
was reduced from 83 minutes to 57 minutes after preopera-
tive injection of Avastin as well as reduction of frequency 
of intraoperative bleeding and use of endodiathermy. Good 
visualization due to absence of signiﬁ  cant intraoperative 
bleeding and easier dissection seem to be the reasons for the 
reduction in the surgical time. Scholda and colleagues (2007), 
reported an extensive obliteration of neovascularization 
with only little intraoperative bleeding during surgery after 
intravitreal Avastin. Chen and Park (2006), after injecting 
avastin in a case of TRD 1 week before surgery, reported 
that most epicenters of neovascularization peeled with blunt 
dissection, suggesting that the recently active neovascular 
complex had regressed and ﬁ  brosed.
In the Avastin-treated cases, no increase in the extent 
of tractional on the retina was observed. This is because of 
the short duration between intravitreal injection and surgery 
which did not exceed 1 week. Scholda and colleagues (2007) 
reported on 10 cases with advanced PDR treated with avastin 
2–3 weeks prior to surgery, the authors reported marked 
contraction of the remaining ﬁ  brous tissue. Arevalo and col-
leagues (2008), reported that time from injection to progress 
or development of TRD had a mean of 13 days (range: 3 to 
31 days). The authors reported development or progression 
of TRD in 11 out of 211 eyes (5.2%) after IVA.
The anatomical and visual results seem comparative in 
both groups. Vision improved in 87% in group 2 and 80% 
in group 1 with 27% achieving VA of 20/50 or better in 
both groups.
Improved vision after vitrectomy is now reported for 
60%–80% of eyes with traction macular detachments man-
aged with membrane dissection and PPV. Approximately 
20% of patients achieve vision of at least 20/40 (Meredith 
1994). In the Diabetic Retinopathy Vitrectomy Study, 
patients with active proliferation and good vision preop-
eratively attained vision of 20/40 or better in 41% eyes 
postoperatively (DRVS 1988). In the current study, 5 cases 
(33%) in group 1 and 6 cases (40%) in group 2 had preopera-
tive vision between 0.05 and 0.1. Thompson and colleagues 
(1986) reported poor initial visual acuity as a predictive factor 
of poor visual prognosis.
Good anatomical results were achieved in both groups, 
however in group 2 this was achieved with short term endot-
amponade (gas or air) in 80% of cases with less frequency 
of second surgery while in group 1, silicone oil use was 
60% with subsequent higher rate of resurgery; silicone oil ± 
cataract surgery. The choice of silicone oil in this group was 
strongly related to bleeding tendency which was minimized 
in group 2 by the IVA. Riedel and colleagues (1990) rec-
ommended that oil use be reserved for cases with advanced 
PDR or intractable PVR. Silicone oil provides the longest 
term tamponade, and has the additional beneﬁ  t of noncritical Clinical Ophthalmology 2008:2(4) 715
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posturing. IOP elevation is rarely a problem in the early 
postoperative period (Flaxel et al 2007). Disadvantages 
include the certainty of cataract formation and the fact that at 
some point, the oil must be removed if visual rehabilitation 
is to be accomplished (Thompson et al 1986). Pearson and 
colleagues (1993) studied the effect of silicone oil removal 
following diabetic vitrectomy and concluded that the eventual 
ﬁ  nal visual outcome in these eyes was encouraging in that 
once cataract and oil were removed; most eyes recovered the 
acuity achieved soon after initial vitrectomy.
Good anatomical results in both groups can be ascribed 
to the improvement in vitrectomy equipment. The use of 
smaller 23 gauge vitrectors offers advantages of being less 
traumatizing and together with the high speed cutter effect 
enabled shaving of membranes very close to the retina with 
minimal trauma. Anterior peripheral retinal cryotherapy 
combined with cryotherapy of sclerotomy sites might be 
helpful adjunct procedures in diabetic vitrectomy for inhibi-
tion of ﬁ  brovascular ingrowth and prevention of recurrent 
vitreous hemorrhage (Yeh et al 2005). Mason and colleagues 
(2006) reported that using cryotherapy around sclerotomy 
sites and endolaser in a near-conﬂ  uent pattern helps to quell 
ﬁ  brovascular ingrowth and subsequent hemorrhage.
So, in the current study, preoperative IVA was helpful in 
achieving the surgical and anatomical goals by reducing the 
time of surgery, reducing the intraoperative and postopera-
tive bleeding and reducing the frequency of using silicone 
oil with subsequent reduction of second surgery. The com-
bination of therapies and interventions as they improve and 
evolve offers the potential to revolutionize the approach to 
the complications of diabetic eye disease.
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